regulatory T cell

Overview

Regulatory T cells, often abbreviated as Tregs, are a specialized subset of CD4+ T lymphocytes that maintain immune tolerance and limit excessive immune activation. They are defined by suppressive function and lineage programs centered on FOXP3, which is widely regarded as an essential transcription factor for Treg development and activity. By restraining effector T-cell responses, Tregs help prevent autoimmunity and tissue damage, but they can also suppress beneficial antitumor immunity when enriched in tumors or other immunosuppressive settings.

Biologically, Tregs act through multiple mechanisms, including inhibitory cytokines, cell-contact-dependent suppression, metabolic competition, and modulation of antigen-presenting and myeloid cells. In recent biomedical research, they are frequently discussed in relation to the tumor microenvironment, immune checkpoint therapy, intestinal tolerance, chronic inflammation, and graft-versus-host disease. Because of this dual role, Tregs are both a therapeutic target for cancer immunotherapy and a therapeutic product in autoimmune disease and transplantation.

Focus of Latest Publications

Recent studies have examined regulatory T cells in a wide range of disease contexts, with a strong emphasis on cancer immunology and immune suppression. In advanced non-small cell lung cancer, elevated frequencies of regulatory T cells near CD3 T cells at baseline were associated with improved outcome to pembrolizumab plus gemcitabine in a phase I/II study, suggesting that spatial immune context may influence response to anti-PD-1 treatment. In other tumor studies, Treg abundance or infiltration was repeatedly linked to immunosuppressive microenvironments and resistance to therapy, including in ovarian cancer, bladder cancer, lung adenocarcinoma, cervical cancer, lymphoma, pancreatic cancer, renal carcinoma, and brain metastases of melanoma.

Several publications specifically described interventions that reduced Treg levels or function to enhance antitumor immunity. An aminated fullerene-based nanoplatform decreased regulatory T-cell levels while increasing T-cell infiltration and activation, consistent with enhanced antitumor immunity. A polymannose-guided photodynamic immunotherapy platform increased CD8+ cytotoxic T-cell infiltration and reduced Treg proportions in tumor tissue. Similarly, glycerol-mediated nose-to-brain codelivery of anti-IL-17 and anti-CD73 antibodies promoted CD8+ T-cell activation and residency, reduced Treg infiltration, and produced a strong antitumor effect in melanoma brain metastases. In another study, a “one-two punch” strategy combining immunometabolic reprogramming with checkpoint blockade was reported to support ipilimumab-mediated depletion of regulatory T cells, thereby enabling robust activation of primed CD8+ T cells.

Other cancer-focused studies emphasized mechanisms that promote Treg differentiation, maintenance, or suppressive function. Tumor-derived exosomes were reported to facilitate immune evasion by impairing cytotoxic T lymphocytes, promoting Treg differentiation, and polarizing macrophages toward an M2 phenotype. SAICAR was described as driving T regulatory cell differentiation and FOXP3 maintenance, contributing to immunotherapy resistance. In cervical cancer, elevated IGSF3 expression on tumor cells was identified as a driver of enhanced Treg infiltration and function through TNFR2 on Tregs. In renal carcinoma, VISTA was highlighted as an inhibitory immune checkpoint enriched in myeloid cells and regulatory T cells, underscoring its role as a barrier to effective antitumor immunity. Additional studies linked Treg enrichment with aging-related immunosuppression in ovarian tumors, metabolic checkpoint regulation in anti-PD-1 resistance, and suppressive niches enriched in Tregs and myofibroblastic cancer-associated fibroblasts.

Beyond oncology, Tregs were also studied in immune tolerance and inflammatory disease. A JEM study showed that intestinal regulatory T cells recognizing dietary- or microbiota-derived antigens express RORγt and are essential for immune tolerance in the intestine, while B7 costimulation was reported to antagonize these RORγt+ Treg cells. Spatial transcriptomics in inflammatory bowel disease identified regulatory T cell-associated biology in both disease subtypes, reinforcing their relevance in mucosal immune homeostasis. In bovine coronavirus-infected calf jejunum, a deoxycholic acid deficiency was linked to Th17/Treg imbalance, with suppression of Treg differentiation proposed as part of the pathology. In sepsis and acute pancreatitis, regulatory T cells were described as modulators of immune responses, and serum CCL1 was evaluated as a discriminator of infectious versus sterile systemic inflammation.

Tregs were also central in transplantation and autoimmune research. Impaired Treg recovery in chronic graft-versus-host disease motivated clinical studies aimed at increasing peripheral Treg numbers, including phase 1/2 trials of donor regulatory T cells. Preclinical work on engineered regulatory T cells for IPEX and other autoimmune disorders highlighted FOXP3-dependent lineage commitment and function, supporting the therapeutic use of Treg infusions. Related immunomodulatory studies included belatacept and calcineurin inhibitor contexts, where T-cell regulation is clinically relevant, as well as freshly isolated donor-derived Treg infusions and CliniMACS-based cell processing.

Across these studies, Tregs were consistently positioned as a key determinant of immune balance: protective in tolerance and autoimmunity, but often detrimental in cancer by suppressing cytotoxic T-cell activity and supporting immune escape. Their abundance, phenotype, and spatial organization were repeatedly associated with clinical outcome, immune checkpoint responsiveness, and the broader composition of the tumor microenvironment, including macrophages, dendritic cells, and CD8+ T cells.

Key Publications

• Jun Divergent macrophage-regulated T cell states determine response to Bacillus Calmette-Guérin vaccine in high-risk bladder cancer. (The Journal of clinical investigation, 2026, PMID 42081487): "By contrast, nonresponders showed increased CD8+ T cell exhaustion and Treg cells."
• May Polymannose-Guided Repolarization of Tumor-Associated Macrophages for Enhanced Photodynamic Immunotherapy. (ACS macro letters, 2026, PMID 42050361): "In vivo experiments demonstrated that FI@PMD increased the infiltration of CD8+ cytotoxic T cells in tumor tissues to 2.85-fold of that in the PBS group while reducing the proportion of Treg cells to 0.86-fold."
• May Identification of Mitochondrial Dysfunction-Related Candidate Biomarkers and Analysis of the Immune Cell Infiltration in Epilepsy. (Molecular neurobiology, 2026, PMID 42128965): "Immune infiltration analysis revealed a substantial increase in the abundance of myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs)."
• May Glycerol-mediated nose-to-brain codelivery of anti-IL-17 and anti-CD73 antibodies enhances immunotherapy for melanoma brain metastases. (Science advances, 2026, PMID 42127192): "Ultimately, this combination promoted CD8+ T cell activation and residency, pro-inflammatory macrophage polarization, and reduced Treg cell infiltration, thereby eliciting a strong antitumor effect."
• May Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated advanced non-small cell lung cancer (NSCLC). (Oncoimmunology, 2026, PMID 42126144): "...elevated frequencies of regulatory T cells near CD3 T cells at baseline were associated with improved outcome to treatment (p<0.05)."
• May Multi-Omics and network-based exploration of potential molecular pathways in heart failure relevant to left bundle branch pacing response heterogeneity: Immune remodeling, hub gene identification, and drug repurposing hypotheses. (PloS one, 2026, PMID 42113804): "Immune analysis showed significant alterations in B cell memory, plasma cells, CD8 T cells, regulatory T cells, NK cells, monocytes, macrophages (M0/M1/M2), dendritic cells, and mast cells."
• May Phase 1/2 trials of donor regulatory T cells for the treatment of steroid-refractory chronic graft-versus-host disease. (Blood advances, 2026, PMID 41637631): "Impaired regulatory T-cell (Treg) recovery in patients with cGVHD has led to clinical studies aiming to increase peripheral Treg numbers."
• May SAICAR Drives T Regulatory Cell Differentiation and FOXP3 Maintenance to Promote Immunotherapy Resistance. (Cancer research, 2026, PMID 41671386): "Regulatory T (Treg) cells within the tumor microenvironment critically undermine the efficacy of PD-1 immune checkpoint blockade."
• May VISTA neutralization by immunization reprograms immunosuppression and augments vaccine efficacy in renal carcinoma. (Journal for immunotherapy of cancer, 2026, PMID 42103357): "V-domain Ig suppressor of T-cell activation (VISTA), an inhibitory immune checkpoint enriched in myeloid cells and regulatory T cells (Tregs), represents a critical barrier to effective antitumor immunity."
• May Multi-omics atlas of the bovine coronavirus-infected calf jejunum: reduction of Phocaeicola coprophilus and deoxycholic acid linked to Th17/Treg imbalance. (NPJ biofilms and microbiomes, 2026, PMID 42098175): "We suggested a putative that DCA deficiency might contribute to the pathological polarization of CD4+ T cells toward a Th17 phenotype while suppressing Treg differentiation."